MedTrace Logo

Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid Tumors

NCT03596593 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8000

Last updated 2018-07-24

No results posted yet for this study

Summary

This is a molecular epidemiological investigation aiming to identify microsatellite instability status from circulating tumor DNA in Chinese patients with refractory advanced solid tumors.

Conditions

Interventions

DIAGNOSTIC_TEST

SPANOM (identifying MSI status from ctDNA)

SPANOM technique, which has been developed by 3D Medicines Inc. Shanghai, China and made it possible to identify MSI status from blood samples, will be used in patients with refractory advanced solid tumors.

Sponsors & Collaborators

  • Peking University

    lead OTHER

Principal Investigators

  • Shen Lin, Professor · Peking University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-11
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03596593 on ClinicalTrials.gov